Next Article in Journal
Galectin Binding to Neo-Glycoproteins: LacDiNAc Conjugated BSA as Ligand for Human Galectin-3
Next Article in Special Issue
Bacterial Genotoxins: Merging the DNA Damage Response into Infection Biology
Previous Article in Journal
Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson’s Disease Brains Are Differentially Generated in Mammalian Cell Models
Previous Article in Special Issue
Transcription Blockage Leads to New Beginnings
Article Menu

Export Article

Open AccessReview
Biomolecules 2015, 5(3), 1652-1670; doi:10.3390/biom5031652

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy

School of Molecular Biosciences, College of Veterinary Medicine, Washington State University, Mail Drop 64-7520, Pullman, WA 99164, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Wolf-Dietrich Heyer, Thomas Helleday and Fumio Hanaoka
Received: 22 May 2015 / Accepted: 14 July 2015 / Published: 22 July 2015
(This article belongs to the Special Issue DNA Damage Response)
View Full-Text   |   Download PDF [636 KB, uploaded 22 July 2015]   |  

Abstract

Most chemotherapy regimens contain at least one DNA-damaging agent that preferentially affects the growth of cancer cells. This strategy takes advantage of the differences in cell proliferation between normal and cancer cells. Chemotherapeutic drugs are usually designed to target rapid-dividing cells because sustained proliferation is a common feature of cancer [1,2]. Rapid DNA replication is essential for highly proliferative cells, thus blocking of DNA replication will create numerous mutations and/or chromosome rearrangements—ultimately triggering cell death [3]. Along these lines, DNA topoisomerase inhibitors are of great interest because they help to maintain strand breaks generated by topoisomerases during replication. In this article, we discuss the characteristics of topoisomerase (DNA) I (TOP1) and its inhibitors, as well as the underlying DNA repair pathways and the use of TOP1 inhibitors in cancer therapy. View Full-Text
Keywords: topoisomerase (DNA) I (TOP1); anticancer therapy; DNA replication; topoisomerase inhibitor; DNA double-strand break (DSB); DSB repair; homologous recombination (HR); non-homologous end joining; single-strand break (SSB) repair; one-ended DSB topoisomerase (DNA) I (TOP1); anticancer therapy; DNA replication; topoisomerase inhibitor; DNA double-strand break (DSB); DSB repair; homologous recombination (HR); non-homologous end joining; single-strand break (SSB) repair; one-ended DSB
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Xu, Y.; Her, C. Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy. Biomolecules 2015, 5, 1652-1670.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top